American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 | Latest News RSS feed

American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 - Latest News


American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 ...

INGELHEIM, Germany & INDIANAPOLIS, Ind. — A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its ... read more

ACC recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes

A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the ... read more

Cardiology association recommends Lilly's Jardiance for lowering CV risk in type 2 diabetics

and alliance partner Boehringer Ingelheim announce that the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for reducing cardiovascular (CV) ... read more

Looking for another news?


ACC Consensus on New Diabetes Drugs to Reduce CV Outcomes

The American College of Cardiology has issued an Expert Consensus Decision Pathway aimed at educating cardiologists on the use of two major new classes of diabetes drugs — sodium-glucose cotransporter ... read more


Semaglutide With SGLT2s Reduces A1C, Weight for Those Not Meeting Diabetes Goals

The results come after the American Diabetes Association and the American College of Cardiology have recently issued ... to a sodium glucose co-transporter 2 (SGLT2) inhibitor allowed most patients ... read more

Clear Consensus—Treat Cardiovascular Disease Concurrent with Diabetes

The preferred medications are two novel classes of antidiabetes medications—Sodium-glucose co-transporter-2 (SGLT2) inhibitors ... 1 according to the American College of Cardiology writing committee. ... read more

Real-World Study Data Comparing Empagliflozin vs DPP-4 Inhibitors

Study authors also presented initial safety and efficacy data from EMPRISE at the American College of Cardiology ... 2 (SGLT2) inhibitor currently approved as an adjunct to diet and exercise to ... read more

ADA recommends cardioprotective antihyperglycemic drugs for patients

the American Diabetes Association now recommends that clinicians consider adding agents proved to reduce major cardiovascular events and cardiovascular death – such as the sodium glucose cotransporter ... read more

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

The study, published online ahead of the August 8, 2017, issue of the Journal of the American College of Cardiology ... older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70:704-712. Marx N. ... read more

Duke Study to Examine How Diabetes, Cardiovascular Guidelines Get Into Clinical Practice

For more than a year, the ADA and the American College of Cardiology (ACC) have collaborated closely on recommendations for patients ... makers of the sodium glucose co-transporter 2 (SGLT2) inhibitor ... read more

SGLT-2 Inhibitors Tied to Less Death, HF, MI, Stroke: CVD REAL 2

presented these findings from the Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors 2 (CVD-REAL 2) study here at the American College of Cardiology (ACC) 2018 ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us